Clinical Trial

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is a Phase 1 dose-escalation and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV111. The study will enroll patients with relapsed/refractory large B-cell lymphoma (LBCL) and chronic lymphocytic leukemia (CLL).
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2024-07-25; most recent amendment 2026-05-26.
Status change: Not Yet Recruiting → Recruiting 2024-12-04
Trial Details
NCT Number NCT06528301
Lead Sponsor Umoja Biopharma
Conditions Lymphoma, B-Cell, Lymphoma, Non-Hodgkin (NHL), Lymphoma, Large B-Cell, Diffuse (DLBCL), Chronic Lymphocytic Leukemia (CLL)
Enrollment 106 participants
Start Date 2025-03-10
Primary Completion 2029-03 (estimated)
Study Completion 2029-03 (estimated)
Updated on ClinicalTrials.gov 2026-05-28